Evidence map›Paper›PMID 37760474›Full record

ArticleCancers2023

Validation of a Proteomic Signature of Lung Cancer Risk from Bronchial Specimens of Risk-Stratified Individuals.

S M Jamshedur Rahman, Sheau-Chiann Chen, Yi-Ting Wang, Yuqian Gao, Athena A Schepmoes, Thomas L Fillmore, Tujin Shi, Heidi Chen, Karin D Rodland, Pierre P Massion and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

S M Jamshedur RahmanDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Sheau-Chiann ChenDepartment of Biostatistics, Vanderbilt University, Nashville, TN 37203, USA.ORCID 0000-0002-5574-1434
Yi-Ting WangBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
Yuqian GaoBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.ORCID 0000-0003-1646-4515
Athena A SchepmoesBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
Thomas L FillmoreEnvironmental Molecular Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
Tujin ShiBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.ORCID 0000-0002-5592-3588
Heidi ChenDepartment of Biostatistics, Vanderbilt University, Nashville, TN 37203, USA.
Karin D RodlandDepartment of Cell, Developmental, and Cancer Biology, Oregon Health and Science University, Portland, OR 97201, USA.
Pierre P MassionDivision of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Eric L GroganVeterans Affairs Tennessee Valley Healthcare System, Nashville, TN 37232, USA.
Tao LiuBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.ORCID 0000-0001-9529-6550
Pacific Northwest National Laboratory · USVanderbilt University · USVA Tennessee Valley Healthcare System · USOregon Health & Science University · USVanderbilt University Medical Center · US

Funding

Validation of Biomarkers of Risk for the Early Detection of Lung CancerU01CA152662 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DEPPEN, STEPHEN, GROGAN, ERIC L · 2010 to 2025
$12.8M
NCI NIH HHS ACN15006-001, ACN20007-001, U01CA152662NCI NIH HHS U01 CA152662
6 · The paper itself

Abstract

A major challenge in lung cancer prevention and cure hinges on identifying the at-risk population that ultimately develops lung cancer. Previously, we reported proteomic alterations in the cytologically normal bronchial epithelial cells collected from the bronchial brushings of individuals at risk for lung cancer. The purpose of this study is to validate, in an independent cohort, a selected list of 55 candidate proteins associated with risk for lung cancer with sensitive targeted proteomics using selected reaction monitoring (SRM). Bronchial brushings collected from individuals at low and high risk for developing lung cancer as well as patients with lung cancer, from both a subset of the original cohort (batch 1: n = 10 per group) and an independent cohort of 149 individuals (batch 2: low risk (n = 32), high risk (n = 34), and lung cancer (n = 83)), were analyzed using multiplexed SRM assays. ALDH3A1 and AKR1B10 were found to be consistently overexpressed in the high-risk group in both batch 1 and batch 2 brushing specimens as well as in the biopsies of batch 1. Validation of highly discriminatory proteins and metabolic enzymes by SRM in a larger independent cohort supported their use to identify patients at high risk for developing lung cancer.

Indexed as

bronchial epitheliumearly detectionhigh risklung cancerproteomics

Identifiers

PMID37760474
PMCPMC10526486
OpenAlexW4386620970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.